CURING LOCALIZED IMMUNE CONDITIONS

Starting with Type 1 Diabetes

At Rezq Bio, we are transforming the treatment of autoimmune and inflammatory diseases, beginning with Type 1 Diabetes (T1D)

With clinically validated in-human safety, our therapies centered on dendritic cells are designed to treat T1D patients at every stage of the disease - with negligible side effects

The focus of our platform is regional inflammation. This localized approach avoids the harsh effects of systemic immune suppression while creating a versatile foundation for treating a spectrum of inflammatory conditions - without significant therapy modifications

T1D IS A global PROBLEM WITH NO SOLUTION

64k

New U.S. Diagnoses Annually

2M

Patients Currently in the U.S.

18M

Patients Worldwide by 2040

$85B

Economic Impact Globally

NO LONGEr A JUVENILE CONDITION

In a 2023 study from Johns Hopkins Bloomberg School of Public Health:

● Up to 62% of T1D cases develop in patients older than 20 (median 24 years)

● 37% of patients were diagnosed after 30 years

LACK OF EFFECTIVE TREATMENTS

There are no FDA-approved therapies for TID proven to…

● Prevent disease onset

● Arrest its progression or

● Restore insulin production safely

T1D Treatment Approaches

Rezq's Approach

Treats localized problems locally…

Regional targeting avoids systemic effects

Leverages the immune system to address the inflammatory environment completely

Technology supports multi-disease treatment platform without therapeutic modification

Strong preclinical evidence to support immunosuppressant applications

Insulin Therapy

The standard of care is not a solution

Less than 1/3 of patients with T1D in the U.S. are consistently achieving target blood-glucose levels

Daily, lifelong insulin supplementation does not prevent comorbidities such as heart disease, stroke, nephropathy, blindness, foot amputations…

Systemic Therapies

Significant side effects can offset effectiveness

Suppressed immunity to infection

Malignancy

Organ damage

Targeted Therapies

Offer precision with drawbacks

Narrow molecular or pathway focus does not address the problem completely

Disease specific, often with limited applicability

Varying degrees of systemic immunosuppression

Transplants / Implants

Cell transplant and stem cell technologies show promise

Require systemic and lifelong immunosuppressive therapy

Autoimmune attack still continues

platform

Our approach focuses on dendritic cells as they are the regulator cells of the immune system. They can create an inflammatory or tolerant environment

We use our technological platform to convert dendritic cells from a mature (mDC) or inflammatory state, into an immature (iDC) or tolerant state

mDC

iDC

Our lead P1B/2A ready autologous dendritic cell therapy does this ex-vivo while our microsphere loaded version has performed this preclinically in situ with equally strong performance

Through regional targeting, we can turn off unwanted immune responses locally while not suppressing the entire immune system

Pipeline

Rezq’s pipeline is led by our cell therapy designed to treat early onset T1D. With promising in-human safety it provides a launching point for our multi-disease, dual-application and dual delivery method platform

Treatment Pipeline

Therapy Name

Indication

Discovery

Optimization

IND-Enabling

Phase 1A

Phase 1B/2A

RZQ-MC1

Early Onset Type 1 Diabetes

RZQ-MC1 is an autologous dendritic cell therapy, with negligle safety concerns found in a convincing Phase 1A trial. Rezq is planning to launch a Phase 1B/2A to treat early-onset T1D in the next year

RZQ-MC2

Colitis

RZQ-MC2 uses Rezq's autologous dendritic cell therapy to treat patients with Colitis and IBD related diseases. The preclinical work helped validate Rezq's regional treatment approach

RZQ-CC1

Various Indications

RZQ-CC1 leverages Rezq's immunosuppresion technologies to support other transplant and implant treatments to reduce or eliminate needs for systemic immunosuppression. Planned partnered preclinical studies will validate previous research findings

RZQ-MM*

Type 1 Diabetes

Rezq is advancing mulitple different microsphere payloads through preclinical testing to provide a small molecule based version of its localized approach enabling broader usage scenarios

people

We have built careers in healthcare and are passionate about curing T1D and autoimmune disease

People – Spotlight

Arjun Hattiangadi MBA, MS

CEO and Founder

tap for details

Doug Greene, MD

Head R&D

tap for details

Howard Foyt, MD, PhD

CMO

tap for details

Nick Giannoukakis, PhD

CSO and Founder

tap for details

Elina Linetsky, PhD

VP of Process, Dev and Mfg

tap for details

Don Very, PhD

Immunology Principal

tap for details

Seth Zimmerman, JD, MBA

VP of Finance

tap for details

Myra Frick

Clinical Coordinator

tap for details

Arjun Hattiangadi MBA, MS

CEO and Founder

tap for details

Doug Greene, MD

Head R&D

tap for details

Howard Foyt, MD, PhD

CMO

tap for details

Nick Giannoukakis, PhD

CSO and Founder

tap for details

Elina Linetsky, PhD

VP of Process, Dev and Mfg

tap for details

Don Very, PhD

Immunology Principal

tap for details

Seth Zimmerman, JD, MBA

VP of Finance

tap for details

Myra Frick

Clinical Coordinator

tap for details

scroll for more

Board and Advisory

We are fortunate to have an accomplished Board and Advisory that believe in our team, science and mission to treat autoimmune disease

Board & Advisors – v2

James Nolan

Board Chair

tap for details

Stan Marks, MD

Board Member

tap for details

Massimo Trucco, MD

Advisor and Founder

tap for details

David Finegold, MD

Advisor and Founder

tap for details

Orville Kolterman, MD

Advisor

tap for details

Philip Raskin, MD

Advisor

tap for details

Robert Pearlman

Advisor

tap for details

James Nolan

Board Chair

tap for details

Stan Marks, MD

Board Member

tap for details

Massimo Trucco, MD

Advisor and Founder

tap for details

David Finegold, MD

Advisor and Founder

tap for details

Orville Kolterman, MD

Advisor

tap for details

Philip Raskin, MD

Advisor

tap for details

Robert Pearlman

Advisor

tap for details

scroll for more